Syndax Pharmaceuticals (FRA:1T3) GF Score: 25/100 (As of Jul. 13, 2026) — 40% Below Median


FRA:1T3 Syndax Pharmaceuticals Inc FRA:1T3
25 GF Score
Price €21.28
! 9 Warning Signs
View Full Analysis

What is Syndax Pharmaceuticals GF Score?

Syndax Pharmaceuticals FRA:1T3 -0.61% 25 GF Score is 25 as of Jul. 13, 2026, which is 40% below its 10-year median of 42.00. GuruFocus rates FRA:1T3 with a GF Score™ of 25/100. The stock has 9 warning signs investors should review.

Syndax Pharmaceuticals has the GF Score of 25, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 3/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 2/10
5. Momentum Rank : 6/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Syndax Pharmaceuticals might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Syndax Pharmaceuticals  (FRA:1T3) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Syndax Pharmaceuticals GF Score Related Terms

FRA:1T3 vs IOVA, GLUE, TYRA: GF Score Comparison

For the Biotechnology subindustry, Syndax Pharmaceuticals's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syndax Pharmaceuticals GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's GF Score distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's GF Score falls into.


FRA:1T3
25GF Score
Syndax Pharmaceuticals Inc FRA:1T3
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 25 mean?
Syndax Pharmaceuticals (FRA:1T3) has a GF Score of 25 as of Jul. 13, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Syndax Pharmaceuticals and its competitors. This is 40% below median its historical median of 42.00. Over the past decade, Syndax Pharmaceuticals' GF Score has ranged from 14.00 to 69.00.
Is Syndax Pharmaceuticals' GF Score too high?
Syndax Pharmaceuticals' current GF Score of 25 is 40% below median its 10-year median of 42.00. Over the past 10 years, this metric has ranged from a low of 14.00 to a high of 69.00. Overall, Syndax Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' GF Score compare to IOVA and GLUE?
Syndax Pharmaceuticals' GF Score of 25 can be compared against companies in the Biotechnology industry. Historically, Syndax Pharmaceuticals' own GF Score has ranged from 14.00 to 69.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Syndax Pharmaceuticals and its competitors. Syndax Pharmaceuticals's current GF Score is 25, which is 40% below median its own 10-year median of 42.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Syndax Pharmaceuticals (FRA:1T3) has a current GF Score of 25. The current GF Score is 25, which is 40% below median its 10-year median of 42.00. Syndax Pharmaceuticals' overall GF Score™ is 25/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current GF Score is 25 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syndax Pharmaceuticals Business Description

Other Exchanges SNDX:USA1T3:Germany
Address 730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
25GF Score

Get the complete analysis for FRA:1T3

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.28
Price